Clinical Report: Insights from Robert Wethman on Analytical Science in Pharma
Overview
Robert Wethman discusses the evolving role of analytical science in pharmaceutical development, emphasizing the need for strategic alignment and effective implementation of technologies like real-time spectroscopy. He highlights the challenges posed by increasing complexity in drug manufacturing and the importance of collaboration in overcoming analytical bottlenecks.
Background
The role of analytical science is critical in pharmaceutical manufacturing, providing reliable methods that support drug development. As therapeutics become more complex, the integration of advanced analytical techniques is essential for maintaining efficiency and accuracy in the production process. Understanding these dynamics is vital for professionals in the biopharma sector to navigate the challenges of modern drug development.
Data Highlights
No numerical or trial data available in the source material.
Key Findings
- Analytical science is increasingly viewed as a strategic driver in pharmaceutical organizations.
- Real-time spectroscopic monitoring can enhance the efficiency of drug development processes.
- Successful implementation of new analytical methods requires early knowledge sharing and collaboration with operations.
- Complexity in drug manufacturing processes creates significant analytical bottlenecks that need to be addressed.
- At-line spectroscopy has shown practical benefits and serves as a bridge towards full real-time monitoring.
Clinical Implications
The integration of advanced analytical methods like real-time spectroscopy is essential for improving drug development timelines and outcomes. Professionals in the field must prioritize collaboration and strategic alignment to effectively implement these technologies.
Conclusion
The future of biopharma will depend on the effective application of analytical science, particularly as the complexity of drug development continues to increase.
Related Resources & Content
- The Analytical Scientist, Frontline Pharma: Tao Chen, 2026 -- Insights on Drug Development
- The ASCO Post, Expert Point of View: Howard (Jack) West, MD, and William R. Sellers, 2020 -- Perspectives on KRAS G12C Mutation
- The Analytical Scientist, Frontline Pharma: Sarah O’Keeffe, 2026 -- Innovations in Drug Synthesis
- FDA Guidance, Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products, 2026 -- Regulatory Framework
- ScienceDirect, Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4), 2025 -- Updated Analysis
- The ASCO Post — Expert Point of View: Winald Gerritsen, MD, PhD
- Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials
- Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application | FDA
- Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial - ScienceDirect
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
About the Author(s)
James Strachan
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.
